News from AGA

Our patients face racial health disparities daily, leading to inequalities in care and poorer health outcomes. AGA is bringing together the GI community to fund health disparities research with the goal of improving care for the patients who rely on us.

At this important moment in history, the AGA Research Foundation is uniquely qualified to push forward innovative research in health disparities in gastroenterology. With donations from AGA members to our new initiative called AGA Giving Day, we can provide researchers with a secure source of funding that helps understand the causes of known health disparities, understand why the disparity exists, and develop interventions to reduce and eliminate health disparities.

The AGA Research Foundation invites you to support AGA Giving Day today through Dec. 3. Contributors will be recognized as supporters of our fight to achieve equity and eradicate disparities in digestive diseases.

Learn more at gastro.org/agagivingday.


[email protected]

Our patients face racial health disparities daily, leading to inequalities in care and poorer health outcomes. AGA is bringing together the GI community to fund health disparities research with the goal of improving care for the patients who rely on us.

At this important moment in history, the AGA Research Foundation is uniquely qualified to push forward innovative research in health disparities in gastroenterology. With donations from AGA members to our new initiative called AGA Giving Day, we can provide researchers with a secure source of funding that helps understand the causes of known health disparities, understand why the disparity exists, and develop interventions to reduce and eliminate health disparities.

The AGA Research Foundation invites you to support AGA Giving Day today through Dec. 3. Contributors will be recognized as supporters of our fight to achieve equity and eradicate disparities in digestive diseases.

Learn more at gastro.org/agagivingday.


[email protected]

Our patients face racial health disparities daily, leading to inequalities in care and poorer health outcomes. AGA is bringing together the GI community to fund health disparities research with the goal of improving care for the patients who rely on us.

At this important moment in history, the AGA Research Foundation is uniquely qualified to push forward innovative research in health disparities in gastroenterology. With donations from AGA members to our new initiative called AGA Giving Day, we can provide researchers with a secure source of funding that helps understand the causes of known health disparities, understand why the disparity exists, and develop interventions to reduce and eliminate health disparities.

The AGA Research Foundation invites you to support AGA Giving Day today through Dec. 3. Contributors will be recognized as supporters of our fight to achieve equity and eradicate disparities in digestive diseases.

Learn more at gastro.org/agagivingday.


[email protected]

Ninety percent of patients tracked in the AGA FMT National Registry were cured of Clostridioides difficile infection with few serious side effects.

AGA has released the first results from the NIH-funded AGA Fecal Microbiota Transplantation (FMT) National Registry, the largest real-world study on the safety and effectiveness of FMT. Published in Gastroenterology, the registry reported that FMT led to a cure of C. difficile infection in 90% of patients across 20 North American FMT practice sites. Few serious side effects were reported.

“While the value of fecal microbiota transplantation for treating recurrent C. difficile infection is clear from research studies, the potential long-term consequences of altering a patient’s gut microbiota are not fully known,” says Colleen R. Kelly, MD, AGAF, associate professor of medicine at Brown University in Providence, R.I. and co-principal investigator of the AGA FMT National Registry. “Releasing the initial results of the AGA FMT National Registry is an important step toward understanding the true risks and benefits of microbiota therapeutics in a real-world setting.”

This new report details effectiveness and safety outcomes from the first 259 patients enrolled in the registry between December 2017 and September 2019. Almost all participants received FMT using an unknown donor from stool banks. The most common method of FMT delivery was colonoscopy followed by upper endoscopy. Of the 222 participants who returned for the one-month follow-up, 200 participants (90%) had their C. difficile infection cured with 197 of those requiring only a single FMT. Infections were reported in 11 participants, but only 2 were thought to be possibly related to the procedure. FMT response was deemed durable, with recurrence of C. difficile infection in the 6 months after successful FMT occurring in only 4% of participants. This data includes patients with comorbidities, such as inflammatory bowel disease and immunocompromised status, who are typically excluded from FMT clinical trials.

“These initial results show a high success rate of FMT in the real-world setting. We’ll continue to track these patients for 10 years to assess long-term safety, which will be critical to determining the full safety profile of FMT,” added Dr. Kelly.
 

[email protected]

Ninety percent of patients tracked in the AGA FMT National Registry were cured of Clostridioides difficile infection with few serious side effects.

AGA has released the first results from the NIH-funded AGA Fecal Microbiota Transplantation (FMT) National Registry, the largest real-world study on the safety and effectiveness of FMT. Published in Gastroenterology, the registry reported that FMT led to a cure of C. difficile infection in 90% of patients across 20 North American FMT practice sites. Few serious side effects were reported.

“While the value of fecal microbiota transplantation for treating recurrent C. difficile infection is clear from research studies, the potential long-term consequences of altering a patient’s gut microbiota are not fully known,” says Colleen R. Kelly, MD, AGAF, associate professor of medicine at Brown University in Providence, R.I. and co-principal investigator of the AGA FMT National Registry. “Releasing the initial results of the AGA FMT National Registry is an important step toward understanding the true risks and benefits of microbiota therapeutics in a real-world setting.”

This new report details effectiveness and safety outcomes from the first 259 patients enrolled in the registry between December 2017 and September 2019. Almost all participants received FMT using an unknown donor from stool banks. The most common method of FMT delivery was colonoscopy followed by upper endoscopy. Of the 222 participants who returned for the one-month follow-up, 200 participants (90%) had their C. difficile infection cured with 197 of those requiring only a single FMT. Infections were reported in 11 participants, but only 2 were thought to be possibly related to the procedure. FMT response was deemed durable, with recurrence of C. difficile infection in the 6 months after successful FMT occurring in only 4% of participants. This data includes patients with comorbidities, such as inflammatory bowel disease and immunocompromised status, who are typically excluded from FMT clinical trials.

“These initial results show a high success rate of FMT in the real-world setting. We’ll continue to track these patients for 10 years to assess long-term safety, which will be critical to determining the full safety profile of FMT,” added Dr. Kelly.
 

[email protected]

Ninety percent of patients tracked in the AGA FMT National Registry were cured of Clostridioides difficile infection with few serious side effects.

AGA has released the first results from the NIH-funded AGA Fecal Microbiota Transplantation (FMT) National Registry, the largest real-world study on the safety and effectiveness of FMT. Published in Gastroenterology, the registry reported that FMT led to a cure of C. difficile infection in 90% of patients across 20 North American FMT practice sites. Few serious side effects were reported.

“While the value of fecal microbiota transplantation for treating recurrent C. difficile infection is clear from research studies, the potential long-term consequences of altering a patient’s gut microbiota are not fully known,” says Colleen R. Kelly, MD, AGAF, associate professor of medicine at Brown University in Providence, R.I. and co-principal investigator of the AGA FMT National Registry. “Releasing the initial results of the AGA FMT National Registry is an important step toward understanding the true risks and benefits of microbiota therapeutics in a real-world setting.”

This new report details effectiveness and safety outcomes from the first 259 patients enrolled in the registry between December 2017 and September 2019. Almost all participants received FMT using an unknown donor from stool banks. The most common method of FMT delivery was colonoscopy followed by upper endoscopy. Of the 222 participants who returned for the one-month follow-up, 200 participants (90%) had their C. difficile infection cured with 197 of those requiring only a single FMT. Infections were reported in 11 participants, but only 2 were thought to be possibly related to the procedure. FMT response was deemed durable, with recurrence of C. difficile infection in the 6 months after successful FMT occurring in only 4% of participants. This data includes patients with comorbidities, such as inflammatory bowel disease and immunocompromised status, who are typically excluded from FMT clinical trials.

“These initial results show a high success rate of FMT in the real-world setting. We’ll continue to track these patients for 10 years to assess long-term safety, which will be critical to determining the full safety profile of FMT,” added Dr. Kelly.
 

[email protected]

In a new practice management commentary, Dr. Meena B. Bansal challenges hepatologists to champion value-based care.

In the September issue of Clinical Gastroenterology and Hepatology, Meena B. Bansal, MD, FAASLD, from Icahn School of Medicine at Mount Sinai, New York, provides clinicians with practical guidance on their essential role in value-based health care. Read the article, which appears in CGH’s Practice Management: The Road Ahead column: How Hepatologists Can Contribute to Value-Based Care.

Since hepatologists care for some of the sickest patients in the system, their role in documenting and managing chronic conditions is paramount to a system’s success in value-based care. Hepatologists can expand their reach by:

• Advocating for improvement of coding specificity.
• Participating in quality improvement work.
• Supporting efforts to create a shift in the cost curve for their high-risk patients.

By highlighting how they can shift the cost curve while improving outcomes, they can advocate for the additional resources needed to care for this high-risk population and can have the opportunity to show the return on investment. With this outlook, hepatologists who “engage” rather than “react” can make a real impact on system leadership and play a key role in this dynamic health care landscape.

Read the full article in the September issue of Clinical Gastroenterology and Hepatology.
 

[email protected]

In a new practice management commentary, Dr. Meena B. Bansal challenges hepatologists to champion value-based care.

In the September issue of Clinical Gastroenterology and Hepatology, Meena B. Bansal, MD, FAASLD, from Icahn School of Medicine at Mount Sinai, New York, provides clinicians with practical guidance on their essential role in value-based health care. Read the article, which appears in CGH’s Practice Management: The Road Ahead column: How Hepatologists Can Contribute to Value-Based Care.

Since hepatologists care for some of the sickest patients in the system, their role in documenting and managing chronic conditions is paramount to a system’s success in value-based care. Hepatologists can expand their reach by:

• Advocating for improvement of coding specificity.
• Participating in quality improvement work.
• Supporting efforts to create a shift in the cost curve for their high-risk patients.

By highlighting how they can shift the cost curve while improving outcomes, they can advocate for the additional resources needed to care for this high-risk population and can have the opportunity to show the return on investment. With this outlook, hepatologists who “engage” rather than “react” can make a real impact on system leadership and play a key role in this dynamic health care landscape.

Read the full article in the September issue of Clinical Gastroenterology and Hepatology.
 

[email protected]

In a new practice management commentary, Dr. Meena B. Bansal challenges hepatologists to champion value-based care.

In the September issue of Clinical Gastroenterology and Hepatology, Meena B. Bansal, MD, FAASLD, from Icahn School of Medicine at Mount Sinai, New York, provides clinicians with practical guidance on their essential role in value-based health care. Read the article, which appears in CGH’s Practice Management: The Road Ahead column: How Hepatologists Can Contribute to Value-Based Care.

Since hepatologists care for some of the sickest patients in the system, their role in documenting and managing chronic conditions is paramount to a system’s success in value-based care. Hepatologists can expand their reach by:

• Advocating for improvement of coding specificity.
• Participating in quality improvement work.
• Supporting efforts to create a shift in the cost curve for their high-risk patients.

By highlighting how they can shift the cost curve while improving outcomes, they can advocate for the additional resources needed to care for this high-risk population and can have the opportunity to show the return on investment. With this outlook, hepatologists who “engage” rather than “react” can make a real impact on system leadership and play a key role in this dynamic health care landscape.

Read the full article in the September issue of Clinical Gastroenterology and Hepatology.
 

[email protected]

Physicians with difficult patient scenarios regularly bring their questions to the AGA Community (https://community.gastro.org) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. The upgraded networking platform now features a newsfeed for difficult patient scenarios and regularly scheduled Roundtable discussions with experts in the field.

In case you missed it, here are some clinical discussions and Roundtables in the newsfeed this month:
 

• Initial results from the FMT National Registry (https://community.gastro.org/posts/22693)
• Practice update: Reducing rates of post endoscopy esophageal adenocarcinoma (https://community.gastro.org/posts/22805)
• Patient case: Eosinophilic gastrointestinal disease (https://community.gastro.org/posts/22743)
• Patient case: Repeat colonoscopy following splenic injury (https://community.gastro.org/posts/22739)
• Windows on Clinical GI Roundtables: Crohn’s disease and gastroparesis

View upcoming Roundtables in the community at https://community.gastro.org/discussions.
 

Physicians with difficult patient scenarios regularly bring their questions to the AGA Community (https://community.gastro.org) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. The upgraded networking platform now features a newsfeed for difficult patient scenarios and regularly scheduled Roundtable discussions with experts in the field.

In case you missed it, here are some clinical discussions and Roundtables in the newsfeed this month:
 

• Initial results from the FMT National Registry (https://community.gastro.org/posts/22693)
• Practice update: Reducing rates of post endoscopy esophageal adenocarcinoma (https://community.gastro.org/posts/22805)
• Patient case: Eosinophilic gastrointestinal disease (https://community.gastro.org/posts/22743)
• Patient case: Repeat colonoscopy following splenic injury (https://community.gastro.org/posts/22739)
• Windows on Clinical GI Roundtables: Crohn’s disease and gastroparesis

View upcoming Roundtables in the community at https://community.gastro.org/discussions.
 

Physicians with difficult patient scenarios regularly bring their questions to the AGA Community (https://community.gastro.org) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. The upgraded networking platform now features a newsfeed for difficult patient scenarios and regularly scheduled Roundtable discussions with experts in the field.

In case you missed it, here are some clinical discussions and Roundtables in the newsfeed this month:
 

• Initial results from the FMT National Registry (https://community.gastro.org/posts/22693)
• Practice update: Reducing rates of post endoscopy esophageal adenocarcinoma (https://community.gastro.org/posts/22805)
• Patient case: Eosinophilic gastrointestinal disease (https://community.gastro.org/posts/22743)
• Patient case: Repeat colonoscopy following splenic injury (https://community.gastro.org/posts/22739)
• Windows on Clinical GI Roundtables: Crohn’s disease and gastroparesis

View upcoming Roundtables in the community at https://community.gastro.org/discussions.
 

Join us for our new GI Forging Forward virtual symposia series, a practical educational training program covering timely topics for GIs through the lens of COVID-19. Experts in the field will present the latest COVID-19 findings, share proven strategies to communicate and manage disaster and crisis situations, and educate participants on evidence-based recommendations to meet today’s evolving needs. Upcoming topics will cover keeping you, your staff and patients safe, new approaches and training in research, leading in times of crisis, and rapid-response guideline development.

Registration for this month’s virtual webinars are now open:

• Meet NIH Leadership: Minorities health disparities, research and career development: Oct. 15, 2020, 5:30 p.m. EDT
• Effective leadership in times of crisis: Oct. 22, 2020, 5:30 p.m. EDT

For more information, visit www.gastro.org/GIForgingForward.

[email protected]

Join us for our new GI Forging Forward virtual symposia series, a practical educational training program covering timely topics for GIs through the lens of COVID-19. Experts in the field will present the latest COVID-19 findings, share proven strategies to communicate and manage disaster and crisis situations, and educate participants on evidence-based recommendations to meet today’s evolving needs. Upcoming topics will cover keeping you, your staff and patients safe, new approaches and training in research, leading in times of crisis, and rapid-response guideline development.

Registration for this month’s virtual webinars are now open:

• Meet NIH Leadership: Minorities health disparities, research and career development: Oct. 15, 2020, 5:30 p.m. EDT
• Effective leadership in times of crisis: Oct. 22, 2020, 5:30 p.m. EDT

For more information, visit www.gastro.org/GIForgingForward.

[email protected]

Join us for our new GI Forging Forward virtual symposia series, a practical educational training program covering timely topics for GIs through the lens of COVID-19. Experts in the field will present the latest COVID-19 findings, share proven strategies to communicate and manage disaster and crisis situations, and educate participants on evidence-based recommendations to meet today’s evolving needs. Upcoming topics will cover keeping you, your staff and patients safe, new approaches and training in research, leading in times of crisis, and rapid-response guideline development.

Registration for this month’s virtual webinars are now open:

• Meet NIH Leadership: Minorities health disparities, research and career development: Oct. 15, 2020, 5:30 p.m. EDT
• Effective leadership in times of crisis: Oct. 22, 2020, 5:30 p.m. EDT

For more information, visit www.gastro.org/GIForgingForward.

[email protected]

When COVID-19 hit, the AGA Research Foundation quickly announced the AGA-Takeda COVID-19 Rapid Response Research Awards to provide funding to kick-start research into the virus’ impact on the digestive tract. We’re excited to share our three award recipients with you. Read about their research projects below.

David A. Drew, PhD, and Long H. Nguyen, MD, MS, from Massachusetts General Hospital and Harvard Medical School will test their hypothesis that gut microbial communities mediate the relationship between GI symptoms and the varied clinical presentations and outcomes in patients with COVID-19. To accomplish this goal, they will jointly develop and rapidly deploy a multinational digital infrastructure for large-scale epidemiologic studies during the current global pandemic. By characterizing the GI symptoms most predictive of COVID-19 infection risk and severity, their work will offer timely insights into the ongoing pandemic and offer a foundation for further study on the effects of COVID-19 on human gut microbial communities.

Jeffrey Wade Brown from Washington University is evaluating the infective potential of the metaplastic GI foregut. For this project Dr. Brown and his team will use a novel, unique, and unpublished organoid system that propagates the features of upper GI human metaplasia in vitro to study a potential role for metaplasia in the predisposition to COVID-19. Dr. Brown hopes this research will directly help by making a previously naive population know that they are potentially at higher risk. Further, the high-throughput screening technology they are developing will not only be useful here but also could quickly be adapted to other pandemics.

Congratulations to Drs. David A. Drew, Long H. Nguyen, and Jeffrey Wade Brown — recipients of our AGA-Takeda COVID-19 Rapid Response Research Awards from the AGA Research Foundation.

[email protected]

When COVID-19 hit, the AGA Research Foundation quickly announced the AGA-Takeda COVID-19 Rapid Response Research Awards to provide funding to kick-start research into the virus’ impact on the digestive tract. We’re excited to share our three award recipients with you. Read about their research projects below.

David A. Drew, PhD, and Long H. Nguyen, MD, MS, from Massachusetts General Hospital and Harvard Medical School will test their hypothesis that gut microbial communities mediate the relationship between GI symptoms and the varied clinical presentations and outcomes in patients with COVID-19. To accomplish this goal, they will jointly develop and rapidly deploy a multinational digital infrastructure for large-scale epidemiologic studies during the current global pandemic. By characterizing the GI symptoms most predictive of COVID-19 infection risk and severity, their work will offer timely insights into the ongoing pandemic and offer a foundation for further study on the effects of COVID-19 on human gut microbial communities.

Jeffrey Wade Brown from Washington University is evaluating the infective potential of the metaplastic GI foregut. For this project Dr. Brown and his team will use a novel, unique, and unpublished organoid system that propagates the features of upper GI human metaplasia in vitro to study a potential role for metaplasia in the predisposition to COVID-19. Dr. Brown hopes this research will directly help by making a previously naive population know that they are potentially at higher risk. Further, the high-throughput screening technology they are developing will not only be useful here but also could quickly be adapted to other pandemics.

Congratulations to Drs. David A. Drew, Long H. Nguyen, and Jeffrey Wade Brown — recipients of our AGA-Takeda COVID-19 Rapid Response Research Awards from the AGA Research Foundation.

[email protected]

When COVID-19 hit, the AGA Research Foundation quickly announced the AGA-Takeda COVID-19 Rapid Response Research Awards to provide funding to kick-start research into the virus’ impact on the digestive tract. We’re excited to share our three award recipients with you. Read about their research projects below.

David A. Drew, PhD, and Long H. Nguyen, MD, MS, from Massachusetts General Hospital and Harvard Medical School will test their hypothesis that gut microbial communities mediate the relationship between GI symptoms and the varied clinical presentations and outcomes in patients with COVID-19. To accomplish this goal, they will jointly develop and rapidly deploy a multinational digital infrastructure for large-scale epidemiologic studies during the current global pandemic. By characterizing the GI symptoms most predictive of COVID-19 infection risk and severity, their work will offer timely insights into the ongoing pandemic and offer a foundation for further study on the effects of COVID-19 on human gut microbial communities.

Jeffrey Wade Brown from Washington University is evaluating the infective potential of the metaplastic GI foregut. For this project Dr. Brown and his team will use a novel, unique, and unpublished organoid system that propagates the features of upper GI human metaplasia in vitro to study a potential role for metaplasia in the predisposition to COVID-19. Dr. Brown hopes this research will directly help by making a previously naive population know that they are potentially at higher risk. Further, the high-throughput screening technology they are developing will not only be useful here but also could quickly be adapted to other pandemics.

Congratulations to Drs. David A. Drew, Long H. Nguyen, and Jeffrey Wade Brown — recipients of our AGA-Takeda COVID-19 Rapid Response Research Awards from the AGA Research Foundation.

[email protected]

Physicians with difficult patient scenarios regularly bring their questions to the AGA Community (https://community.gastro.org) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. The upgraded networking platform now features a newsfeed for difficult patient scenarios and regularly scheduled Roundtable discussions with experts in the field.

In case you missed it, here are some clinical discussions and Roundtables in the newsfeed this month:
 

• Patient case: Crohn’s patient with three different strictures (https://community.gastro.org/posts/22491)
• Patient case: Alcoholic hepatitis and positive anti-smooth muscle antibody (https://community.gastro.org/posts/22407)
• COVID-19: The importance of preparedness in independent GI practices (https://community.gastro.org/posts/22340)
• Patient case: Crohn’s patient with no tissue (https://community.gastro.org/posts/22472)

Roundtables (https://community.gastro.org/discussions/)

• Roadmap for the future of colorectal cancer screening in the U.S.
• Windows on Clinical GI lecture series: NAFLD, Crohn’s disease and gastroparesis

View all upcoming Roundtables in the community at https://community.gastro.org/discussions.

Physicians with difficult patient scenarios regularly bring their questions to the AGA Community (https://community.gastro.org) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. The upgraded networking platform now features a newsfeed for difficult patient scenarios and regularly scheduled Roundtable discussions with experts in the field.

In case you missed it, here are some clinical discussions and Roundtables in the newsfeed this month:
 

• Patient case: Crohn’s patient with three different strictures (https://community.gastro.org/posts/22491)
• Patient case: Alcoholic hepatitis and positive anti-smooth muscle antibody (https://community.gastro.org/posts/22407)
• COVID-19: The importance of preparedness in independent GI practices (https://community.gastro.org/posts/22340)
• Patient case: Crohn’s patient with no tissue (https://community.gastro.org/posts/22472)

Roundtables (https://community.gastro.org/discussions/)

• Roadmap for the future of colorectal cancer screening in the U.S.
• Windows on Clinical GI lecture series: NAFLD, Crohn’s disease and gastroparesis

View all upcoming Roundtables in the community at https://community.gastro.org/discussions.

Physicians with difficult patient scenarios regularly bring their questions to the AGA Community (https://community.gastro.org) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. The upgraded networking platform now features a newsfeed for difficult patient scenarios and regularly scheduled Roundtable discussions with experts in the field.

In case you missed it, here are some clinical discussions and Roundtables in the newsfeed this month:
 

• Patient case: Crohn’s patient with three different strictures (https://community.gastro.org/posts/22491)
• Patient case: Alcoholic hepatitis and positive anti-smooth muscle antibody (https://community.gastro.org/posts/22407)
• COVID-19: The importance of preparedness in independent GI practices (https://community.gastro.org/posts/22340)
• Patient case: Crohn’s patient with no tissue (https://community.gastro.org/posts/22472)

Roundtables (https://community.gastro.org/discussions/)

• Roadmap for the future of colorectal cancer screening in the U.S.
• Windows on Clinical GI lecture series: NAFLD, Crohn’s disease and gastroparesis

View all upcoming Roundtables in the community at https://community.gastro.org/discussions.

Gastroenterology is proud to announce the release of a special collection of colorectal cancer articles. This curated collection includes some of the top colorectal cancer research published over the last 3 years with new research being added to the collection as it’s published.

View the special collection on Gastroenterology’s website, which is designed to help you quickly scan recent colorectal cancer research and easily navigate to studies of interest. Recent articles include:
 

• Use of Artificial Intelligence-Based Analytics From Live Colonoscopies to Optimize the Quality of the Colonoscopy Examination in Real Time: Proof of Concept
• Risk Factors for Early-Onset Colorectal Cancer
• Causes of Post-Colonoscopy Colorectal Cancers Based on World Endoscopy Organization System of Analysis

To view all of Gastroenterology’s curated article collections, please visit gastro.org/GastroCollections.

[email protected]

Gastroenterology is proud to announce the release of a special collection of colorectal cancer articles. This curated collection includes some of the top colorectal cancer research published over the last 3 years with new research being added to the collection as it’s published.

View the special collection on Gastroenterology’s website, which is designed to help you quickly scan recent colorectal cancer research and easily navigate to studies of interest. Recent articles include:
 

• Use of Artificial Intelligence-Based Analytics From Live Colonoscopies to Optimize the Quality of the Colonoscopy Examination in Real Time: Proof of Concept
• Risk Factors for Early-Onset Colorectal Cancer
• Causes of Post-Colonoscopy Colorectal Cancers Based on World Endoscopy Organization System of Analysis

To view all of Gastroenterology’s curated article collections, please visit gastro.org/GastroCollections.

[email protected]

Gastroenterology is proud to announce the release of a special collection of colorectal cancer articles. This curated collection includes some of the top colorectal cancer research published over the last 3 years with new research being added to the collection as it’s published.

View the special collection on Gastroenterology’s website, which is designed to help you quickly scan recent colorectal cancer research and easily navigate to studies of interest. Recent articles include:
 

• Use of Artificial Intelligence-Based Analytics From Live Colonoscopies to Optimize the Quality of the Colonoscopy Examination in Real Time: Proof of Concept
• Risk Factors for Early-Onset Colorectal Cancer
• Causes of Post-Colonoscopy Colorectal Cancers Based on World Endoscopy Organization System of Analysis

To view all of Gastroenterology’s curated article collections, please visit gastro.org/GastroCollections.

[email protected]

Physicians with difficult patient scenarios regularly bring their questions to the AGA Community (https://community.gastro.org) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. The upgraded networking platform now features a newsfeed for difficult patient scenarios and regularly scheduled Roundtable discussions with experts in the field.

In case you missed it, here are some clinical discussions and Roundtables in the newsfeed this month:

• AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review (https://community.gastro.org/posts/22199)
• Establishing an acute colitis pathway (https://community.gastro.org/posts/22171)
• Preprocedure COVID testing (https://community.gastro.org/posts/22164)
• Patient case: Gastroesophageal varices (https://community.gastro.org/posts/22098)
• Patient case: IBD with intra-abdominal sepsis (https://community.gastro.org/posts/22055)
• Patient case: Hypervascular pancreatic parenchyma (https://community.gastro.org/posts/22039)

Roundtables (https://community.gastro.org/discussions/)

• Windows on Clinical GI
• Clinical Challenges in IBD: Ulcerative colitis and a fistula
• GI COVID-19 Connection: Implementing an effective long-term telehealth program in a post-COVID world

View all upcoming Roundtables in the community at https://community.gastro.org/discussions.

Physicians with difficult patient scenarios regularly bring their questions to the AGA Community (https://community.gastro.org) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. The upgraded networking platform now features a newsfeed for difficult patient scenarios and regularly scheduled Roundtable discussions with experts in the field.

In case you missed it, here are some clinical discussions and Roundtables in the newsfeed this month:

• AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review (https://community.gastro.org/posts/22199)
• Establishing an acute colitis pathway (https://community.gastro.org/posts/22171)
• Preprocedure COVID testing (https://community.gastro.org/posts/22164)
• Patient case: Gastroesophageal varices (https://community.gastro.org/posts/22098)
• Patient case: IBD with intra-abdominal sepsis (https://community.gastro.org/posts/22055)
• Patient case: Hypervascular pancreatic parenchyma (https://community.gastro.org/posts/22039)

Roundtables (https://community.gastro.org/discussions/)

• Windows on Clinical GI
• Clinical Challenges in IBD: Ulcerative colitis and a fistula
• GI COVID-19 Connection: Implementing an effective long-term telehealth program in a post-COVID world

View all upcoming Roundtables in the community at https://community.gastro.org/discussions.

Physicians with difficult patient scenarios regularly bring their questions to the AGA Community (https://community.gastro.org) to seek advice from colleagues about therapy and disease management options, best practices, and diagnoses. The upgraded networking platform now features a newsfeed for difficult patient scenarios and regularly scheduled Roundtable discussions with experts in the field.

In case you missed it, here are some clinical discussions and Roundtables in the newsfeed this month:

• AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review (https://community.gastro.org/posts/22199)
• Establishing an acute colitis pathway (https://community.gastro.org/posts/22171)
• Preprocedure COVID testing (https://community.gastro.org/posts/22164)
• Patient case: Gastroesophageal varices (https://community.gastro.org/posts/22098)
• Patient case: IBD with intra-abdominal sepsis (https://community.gastro.org/posts/22055)
• Patient case: Hypervascular pancreatic parenchyma (https://community.gastro.org/posts/22039)

Roundtables (https://community.gastro.org/discussions/)

• Windows on Clinical GI
• Clinical Challenges in IBD: Ulcerative colitis and a fistula
• GI COVID-19 Connection: Implementing an effective long-term telehealth program in a post-COVID world

View all upcoming Roundtables in the community at https://community.gastro.org/discussions.

AGA has released a new Clinical Practice Update providing best practice advice for clinicians screening and diagnosing pancreatic cancer in high-risk individuals. Screening to detect pancreas cancers and their precursor lesions in high-risk patients can improve survival if it facilitates surgical resection for early-stage disease.

In the AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review, published in Gastroenterology’s July issue, the authors provide 13 best practice advice statements to address key issues in clinical management of these patients.

For more information, visit www.gastro.org/PancreasCPU.

[email protected]

AGA has released a new Clinical Practice Update providing best practice advice for clinicians screening and diagnosing pancreatic cancer in high-risk individuals. Screening to detect pancreas cancers and their precursor lesions in high-risk patients can improve survival if it facilitates surgical resection for early-stage disease.

In the AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review, published in Gastroenterology’s July issue, the authors provide 13 best practice advice statements to address key issues in clinical management of these patients.

For more information, visit www.gastro.org/PancreasCPU.

[email protected]

AGA has released a new Clinical Practice Update providing best practice advice for clinicians screening and diagnosing pancreatic cancer in high-risk individuals. Screening to detect pancreas cancers and their precursor lesions in high-risk patients can improve survival if it facilitates surgical resection for early-stage disease.

In the AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review, published in Gastroenterology’s July issue, the authors provide 13 best practice advice statements to address key issues in clinical management of these patients.

For more information, visit www.gastro.org/PancreasCPU.

[email protected]